Sama Bitarafan1, Aliakbar Saboor-Yaraghi2, Mohammad-Ali Sahraian3, Shahriar Nafissi4, Mansoureh Togha5, Nahid Beladi Moghadam6, Tina Roostaei3, Fereydoun Siassi7, Mohammad-Reza Eshraghian8, Hossein Ghanaati9, Sima Jafarirad10, Behrouz Rafiei9, Mohammad-Hossein Harirchian11. 1. Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2. Department of Molecular and Cellular Nutrition, School of Nutrition and Dietetics, Tehran University of Medical Sciences, Tehran, Iran. 3. Sina MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Neurology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran. 5. Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran. 6. Department of Neurology, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 7. Department of Community Nutrition, Tehran University of Medical Sciences, Tehran, Iran. 8. Department of Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. 9. Advanced Diagnostic and Interventional Radiology Research Center, Medical Imaging Center, Imam Khomeini Hospital, Tehran, Iran. 10. Nutrition and Metabolic Disease Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, Department of Nutrition, School of Paramedicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. 11. Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran. harirchm@sina.tums.ac.ir.
Abstract
BACKGROUND: Many studies have shown that active vitamin A derivatives suppress the formation of pathogenic T cells in multiple sclerosis (MS) patients. The aim of the present study is to determine the impact of vitamin A on disease progression in MS patients. METHODS: A total of 101 relapsing-remitting MS (RRMS) patients were enrolled in a 1-year placebo-controlled randomized clinical trial. The treated group received 25000 IU/d retinyl palmitate for six month followed by 10000 IU/d retinyl palmitate for another six month. The results of the expanded disability status scale (EDSS) and multiple sclerosis functional composite (MSFC) were recorded at the beginning and the end of the study. The relapse rate was recorded during the intervention. Patients underwent baseline and follow up brain MRIs. RESULTS: The results showed "Mean ± SD" of MSFC changes in the treated group was (-0.14 ± 0.20) and in the placebo group was (-0.31 ± 0.19). MSFC was improved significantly (P < 0.001) in the treatment group. There were no significant differences between the "Mean ± SD" of EDSS changes in the treated (0.07 ± 0.23) and placebo (0.08 ± 0.23) groups (P = 0.73). There were also no significant differences between the "Mean ± SD" of annualized relapse rate in the treated group (-0.36 ± 0.56) and placebo (-0.53 ± 0.55) groups (P = 0.20). The "Mean ± SD" of enhanced lesions in the treatment (0.4 ± 1.0) and in the placebo (0.2 ± 0.6) groups were not significantly different (P = 0.26). Volume of T2 hyperintense lesions "Mean ± SD" was not significantly different between treatment (45 ± 137) and placebo (23 ± 112) groups after intervention (P = 0.23). CONCLUSION:Vitamin A improved total MSFC score in RRMS patients, but it did not change EDSS, relapse rate and brain active lesions.
RCT Entities:
BACKGROUND: Many studies have shown that active vitamin A derivatives suppress the formation of pathogenic T cells in multiple sclerosis (MS) patients. The aim of the present study is to determine the impact of vitamin A on disease progression in MSpatients. METHODS: A total of 101 relapsing-remitting MS (RRMS) patients were enrolled in a 1-year placebo-controlled randomized clinical trial. The treated group received 25000 IU/d retinyl palmitate for six month followed by 10000 IU/d retinyl palmitate for another six month. The results of the expanded disability status scale (EDSS) and multiple sclerosis functional composite (MSFC) were recorded at the beginning and the end of the study. The relapse rate was recorded during the intervention. Patients underwent baseline and follow up brain MRIs. RESULTS: The results showed "Mean ± SD" of MSFC changes in the treated group was (-0.14 ± 0.20) and in the placebo group was (-0.31 ± 0.19). MSFC was improved significantly (P < 0.001) in the treatment group. There were no significant differences between the "Mean ± SD" of EDSS changes in the treated (0.07 ± 0.23) and placebo (0.08 ± 0.23) groups (P = 0.73). There were also no significant differences between the "Mean ± SD" of annualized relapse rate in the treated group (-0.36 ± 0.56) and placebo (-0.53 ± 0.55) groups (P = 0.20). The "Mean ± SD" of enhanced lesions in the treatment (0.4 ± 1.0) and in the placebo (0.2 ± 0.6) groups were not significantly different (P = 0.26). Volume of T2 hyperintense lesions "Mean ± SD" was not significantly different between treatment (45 ± 137) and placebo (23 ± 112) groups after intervention (P = 0.23). CONCLUSION:Vitamin A improved total MSFC score in RRMS patients, but it did not change EDSS, relapse rate and brain active lesions.
Authors: M José Bagur; M Antonia Murcia; Antonia M Jiménez-Monreal; Josep A Tur; M Mar Bibiloni; Gonzalo L Alonso; Magdalena Martínez-Tomé Journal: Adv Nutr Date: 2017-05-15 Impact factor: 8.701
Authors: Bruna Yhang da Costa Silva; Helena Alves de Carvalho Sampaio; Nitin Shivappa; James R Hebert; Larissa da Silva Albuquerque; Antônio Augusto Ferreira Carioca; José Artur Costa D'Almeida; Carla Soraya Costa Maia; Maria Luisa Pereira de Melo Journal: Eur J Clin Nutr Date: 2018-09-03 Impact factor: 4.016
Authors: Christoph Ruschil; Evelyn Dubois; Maria-Ioanna Stefanou; Markus Christian Kowarik; Ulf Ziemann; Marcus Schittenhelm; Markus Krumbholz; Felix Bischof Journal: Neurol Res Pract Date: 2021-05-10